December 14, 2020

Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY) a Randomised Controlled Open-Label Platform Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

[Preprint, not peer-reviewed] Receiving azithromycin in addition to usual care was not associated with 28-day mortality (19% vs. 19%) or the duration of hospitalization (12 days vs. 13 days) in a randomized, controlled trial among 7,764 patients hospitalized with COVID-19 in the UK. Results were consistent across subgroups of age, sex, ethnicity, level of respiratory support, days since symptom onset, use of corticosteroids, and baseline predicted risk.

Horby et al. (Dec 14, 2020). Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY) a Randomised Controlled Open-Label Platform Trial. Pre-print downloaded Dec 14 from https://doi.org/10.1101/2020.12.10.20245944